Previous
Next
KEY DATA
PBS listed:
VENCLEXTA in combination with obinutuzumab is PBS listed as a first-line treatment for certain patients with CLL or SLL.1
Visit www.pbs.gov.au for full criteria.
Deep
Response#
#76% (n=163/216) of patients treated with VEN+O achieved peripheral blood uMRD (<1 CLL cell/10,000 leukocytes) 3 months after EOT.2,3
Fixed Treatment Duration‡
‡~1-year treatment duration (treatment complete after 12 x 28 day cycles).2
A Well Characterised Safety Profile¶
¶The most common adverse events (≥20%) of any grade were neutropenia, infusion-related reaction, diarrhoea, thrombocytopenia and pyrexia.2,4 Refer to the Product Information for full safety information.2
DOWNLOADABLE RESOURCES
Initiating VENCLEXTA
PBS Code Summary for VENCLEXTA in 1L and R/R CLL
A summary of the PBS Codes for initiating VENCLEXTA in combination with obinutuzumab (1L CLL) or rituximab (R/R CLL).
Patient information brochure for VENCLEXTA + obinutuzumab treatment (1L CLL)
Share this resource with your 1L CLL patients to help support them during VENCLEXTA + obinutuzumab treatment.
Contact
Discover more about how we can help you in your practice.
PBS Information
Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.
Please review the full Product Information (PI) before prescribing, available below.
CLL: chronic lymphocytic leukaemia. PBS: Pharmaceutical Benefits Scheme. SLL: small lymphocytic lymphoma.
References: 1. Australian Government Department of Health. Schedule of Pharmaceutical Benefits, www.pbs.gov.au. Accessed September 2023. 2. VENCLEXTA Product Information. 3. Fischer K et al. N Engl J Med 2019; 380(23): 2225–36. 4. Al-Sawaf O et al. Lancet Oncol 2020; 21: 1188–200.
AU-VENC-210038 Last revised September 2023